MedicalResearch.com Interview with: Ulrika Nörby MScPharm, PhD Department of E-health and strategic IT Stockholm County Council Sweden MedicalResearch.com: What is the background for this study? What are the main findings? Response: The use of ADHD medication has increased rapidly during the last 10 years, especially among young women. Thereby, questions regarding treatment with these drugs during pregnancy are common. Until now, data concerning fetal safety of ADHD medication have been sparse, especially when it comes to neonatal disorders. For amphetamine preparations, most previous studies concerned illicit drug use during pregnancy, which made it difficult to draw conclusions. Our objective was to estimate birth and neonatal outcomes after maternal use of prescribed ADHD medication during pregnancy. The main findings were that infants exposed to ADHD medication in utero had a somewhat increased risk of neonatal morbidity, especially CNS-related disorders. The odds ratio (OR) for a CNS-disorder was 1.9 for exposed infants compared to non-exposed infants. Further, exposed infants more often needed treatment at a neonatal intensive care unit (NICU), OR 1.5, and were more frequently moderately preterm, OR 1.3. The risk for CNS-related disorders and admission to a NICU was increased also compared to infants whose mothers used ADHD before or after, but not during, pregnancy. This finding suggests a causal relationship between treatment with ADHD medication and the neonatal outcomes. Because of large differences in maternal background characteristics between treated and non-treated women, it is however uncertain to what extent the higher neonatal morbidity is caused by the ADHD medication. (more…)